Number	Histology	2016WHO/ISUP grading system	Hospital stay (days)	Postoperative serum Cr at 1 week (µmol/L)	Complication	Clavien classification	Survival status	Local recurrence	Distant metastasis	Adjuvant therapy
1	Clear cell RCC	3	14	86	Dead	V	Dead	No	No	No
2	Clear cell RCC	2	9	125	–	–	Alive	No	No	Targeted therapy
3	Clear cell RCC	3	14	94	–	–	Dead	Yes	Lung	No
4	Papillary RCC	3	9	111	–	–	Alive	No	Lung	Targeted therapy
5	Clear cell RCC	3	13	116	Venous thrombosis of lower extremities	II	Alive	No	No	Targeted therapy
6	Clear cell RCC	3	12	112	–	–	Loss	No	No	No
7	NB	n/a	15	32	Pulmonary infection	II	Alive	No	No	Targeted therapy
8	Papillary RCC	2	10	87	–	–	Dead	No	No	Targeted therapy
9	Clear cell RCC	4	9	772	Anemia and renal failure	IVa	Dead	No	No	No
10	Clear cell RCC	4	17	79	–	–	Loss	No	No	No
11	Papillary RCC	3	15	75	Anemia	II	Alive	No	No	Targeted therapy
12	Clear cell RCC	3	25	85	–	–	Alive	No	Lung	No
13	Xp11.2 translocation/TFE3 gene fusion RCC	4	14	48	–	–	Alive	No	No	Targeted therapy
14	Clear cell RCC	3	7	93	–	–	Alive	No	No	Targeted therapy
15	NB	n/a	13	65	–	–	Alive	No	No	No

TT, tumor thrombus; Cr, creatinine; ASA, American Society of Anesthesiologists; WHO, World Health Organization; ISUP, International Society of Urological Pathology; NB, nephroblastoma.